CAMBRIDGE, Mass., April 5, 2024 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing novel treatments for severe neurodegenerative diseases, today reported its financial results for the year ended December 31, 2023 and provides a business update….

  

By

Leave a Reply

Your email address will not be published. Required fields are marked *